ArticleFrontiers in immunology2025
Serglycin's role in primary liver cancer: insights into tumor microenvironment and macrophage interaction.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Integrative single-cell and machine learning analysis identifies a tumor doubling time-related prognostic signature and therapeutic targets in head and neck squamous cell carcinoma.Translational oncology · 2026Article
- Integrative single-cell and spatial transcriptomics analysis reveals a baicalein-responsive 10-gene signature for non-small cell lung cancer.Translational oncology · 2026Article
- Serglycin Across the Disease Spectrum: A Multifunctional Proteoglycan in Inflammation and Cancer.Current issues in molecular biology · 2026Article
- Single-cell analysis of TIGD genes in hepatocellular carcinoma: Prognostic value and functional characterization.Translational oncology · 2026Article
- Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma.Frontiers in immunology · 2026Article
- AJUBA: The Master Regulator Bridging EMT and Immune Evasion in Colorectal Cancer.Mediators of inflammation · 2026Article
- Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review.Frontiers in pharmacology · 2026Review
- Multi-omics and spatial transcriptomics decode the ZDHHC9-driven hypoxia-immunosuppressive axis in hepatocellular carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serglycin (SRGN) is an important proteoglycan that regulates tumorigenesis, but its role in primary liver cancer (PLC) remains unclear. Methods: We investigated the expression and prognostic potential of SRGN in PLC using bioinformatics analyses. HepG2 cells were transfected with an SRGN over expression vector and their proliferation, migration, invasion, resistance to sorafenib, and angiogenic capacity were examined Results: Single-cell analysis revealed SRGN expression across 17 distinct cell subpopulations, with higher expression in macrophages in tumor tissues compared to those in normal tissues. SRGN displayed consistent high expression across cell cycle phases while exhibited dynamic expression during macrophage pseudotime trajectory. Cell communication analysis indicated that SRGN was involved in interactions within the tumor microenvironment (TME), particularly in the VEGF signaling network. Autocrine SRGN promoted Conclusions: Our findings highlight the role of SRGN in the TME of PLC. SRGN-high TAMs are induced by paracrine SRGN from hepatoma cells, establishing a self-reinforcing mechanism that drives PLC progression. Therapeutic strategies targeting SRGN should take into account its context-specific roles depending on TME cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.